Non-small cell lung carcinoma: molecular genetics with consideration of cytologic samples

Baum, Jordan E.; Saqi, Anjali; Heymann, Jonas J.

doi:10.1016/j.mpdhp.2018.08.003

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant differences in classification and grading of neuroendocrine tumours are commonly present between the lung and rest of the extra‐pulmonary sites. In most other sites, the neuroendocrine tumours are classified into three grades, whereas, the pulmonary tumours have a different set of terms and classification, including carcinoid, atypical carcinoid, large cell carcinoma, large cell neuroendocrine carcinoma and small cell neuroendocrine carcinoma . The extra‐pulmonary neuroendocrine carcinomas are aggressive .…”

Section: Introductionmentioning

confidence: 99%

“…In most other sites, the neuroendocrine tumours are classified into three grades, whereas, the pulmonary tumours have a different set of terms and classification, including carcinoid, atypical carcinoid, large cell carcinoma, large cell neuroendocrine carcinoma and small cell neuroendocrine carcinoma . The extra‐pulmonary neuroendocrine carcinomas are aggressive . In general terms, neuroendocrine carcinomas (NECs) denote tumours of higher grade, with high mitotic activity and poor differentiation …”

Section: Introductionmentioning

confidence: 99%

“…The extra-pulmonary neuroendocrine carcinomas are aggressive. 3,5 In general terms, neuroendocrine carcinomas (NECs) denote tumours of higher grade, with high mitotic activity and poor differentiation. 3,6 Extra-pulmonary NECs have not been studied much in cytology material.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Neuroendocrine carcinomas: Cytological mimics and diagnostic dilemmas

Gupta

Rohilla

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Neuroendocrine carcinomas (NEC) are rare tumours with multiple morphologic mimics. The cytologist may miss these cases if not aware. Aims and Objects We focused upon the clinical presentation, cytological features and problems in the diagnosis of NEC. Materials and Methods We studied the detailed cytomorphology of 19 cases of NEC (histopathology proved). Results Of these 19 cases of NEC, 15 cases constituted fine needle aspiration (FNA) specimens, one transbronchial needle aspiration specimen, two pleural fluid specimens and a single biliary brushing specimen. All of the FNA specimens were from extra‐pulmonary sites (namely, breast, pancreas, liver and three lymph node FNAs). Eight of the 19 cases (42.1%) showed a significant disparity between cytological and histopathology diagnoses. The break‐up of discordant diagnoses are of adenocarcinoma (three cases), Ewing's sarcoma (one case), infiltrating ductal carcinoma (one case), lymphoma (one case), and squamous cell carcinoma (two cases). The cytology of NECs predominantly showed discrete, round to oval cells with a moderate amount of cytoplasm. The nuclei were pleomorphic, having prominent nucleoli. Occasional cases showed characteristic salt and pepper chromatin and were correctly diagnosed as a neuroendocrine group of tumours. Conclusion The accurate diagnosis of NEC depends on clinical correlation, meticulous screening for any obvious neuroendocrine features and cell block morphology. Immunohistochemistry is essential for ruling out of tumours of neuroendocrine origin. A Ki67 index is mandatory for grading of all neuroendocrine tumours.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroendocrine carcinomas: Cytological mimics and diagnostic dilemmas

Gupta

Rohilla

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

Pulmonary Cytopathology

Heymann,

D’Ambrosio,

Dombrowski

et al. 2024

Surgical Pathology Clinics

View full text Add to dashboard Cite

Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy

Agrawal

Bhattacharya

2022

CDRR

View full text Add to dashboard Cite

Lung cancer is the second leading cancer with a high rate of mortality. It can be treated using different intervention techniques such as chemotherapy, radiation therapy, surgical removal, photodynamic therapy. All of these interventions lack specificity, which implies that it harms the normal cells adjacent to the infected ones. Nanotechnology provides a promising solution that increases the bioavailability of anticancer drugs at the tumor site with reduced toxicity and improved therapeutic efficacy. Nanotechnology also improved the way lung cancer is diagnosed and treated. Various types of nanocarriers like liposomes, polymeric nanoparticles, magnetic nanoparticles, and different theranostic approaches are already approved for medical use, while various are under clinical and preclinical stages. This review article covers the details pertaining to lung cancer, types of overexpressed receptors, and cutting-edge nanocarriers used for treating lung cancer at its specific target.

show abstract

Non-small cell lung carcinoma: molecular genetics with consideration of cytologic samples

Cited by 3 publications

References 25 publications

Neuroendocrine carcinomas: Cytological mimics and diagnostic dilemmas

Neuroendocrine carcinomas: Cytological mimics and diagnostic dilemmas

Pulmonary Cytopathology

Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy

Contact Info

Product

Resources

About